Alliance Global Partners analyst James Molloy initiates coverage on NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy rating and announces Price Target of $7.5.
- Headlines
- Alliance Global Partners Initiates Coverage On NeuroSense Therapeutics With Buy Rating, Announces Price Target of $7.5
Alliance Global Partners Initiates Coverage On NeuroSense Therapeutics With Buy Rating, Announces Price Target of $7.5
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Latest
11:15
The Ministry of Transportation aims to achieve a 10% increase in the national railroad cargo transportation turnover by 2027 compared to 2023.
11:11
Four departments: Encourage insurance companies to increase investment in technology innovation and promote the application of technology such as drones, remote sensing, and the internet of things.
11:10
PG&E Corporation announced the pricing of its common stock and mandatory convertible preferred stock, with the common stock priced at $20.55 per share and the preferred stock priced at $50 per share.